Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5934102 | 0.94 | TRPV1 (0.58) | TRPV1KDM4EP4HTMALDH1A1MEN1 | |
| SCHEMBL5934140 | 0.91 | RAB9A (0.54) | TRPV1KDM4EP4HTMALDH1A1MEN1 | |
| SCHEMBL5934158 | 0.88 | TRPV1 (0.52) | TRPV1KDM4EP4HTMALDH1A1MEN1 | |
| SCHEMBL5934221 | 0.87 | TRPV1 (0.51) | TRPV1P4HTMMEN1KMT2ARAB9A | |
| SCHEMBL5934144 | 0.86 | TRPV1 (0.50) | TRPV1KDM4EP4HTMALDH1A1RAB9A | |
| SCHEMBL5934195 | 0.85 | TRPV1 (0.52) | TRPV1P4HTMALDH1A1MEN1KMT2A | |
| SCHEMBL5934536 | 0.85 | P4HTM (0.58) | KDM4EP4HTMALDH1A1KMT2ARAB9A | |
| SCHEMBL1542970 | 0.84 | RAB9A (0.64) | KDM4EP4HTMALDH1A1MEN1LMNA | |
| SCHEMBL5934345 | 0.84 | PTPN1 (0.59) | TRPV1KDM4EP4HTMALDH1A1RAB9A | |
| SCHEMBL5934385 | 0.83 | RAB9A (0.55) | TRPV1KDM4EALDH1A1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575918-A2 | SUBSTITUTED BIARYL-4-CARBOXYLIC ACID ARYLAMIDE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2005-09-21 | — | — | EP | claimed |
| WO-2004056774-A2 | SUBSTITUTED BIPHENYL-4-CARBOXYLIC ACID ARYLAMIDE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2004-07-08 | — | — | WO | claimed |
| US-20060100245-A1 | Substituted biphenyl-4-carboxylic acid arylamide analogues | NEUROGEN CORPORATION (US) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100245-A1 | Substituted biphenyl-4-carboxylic acid arylamide analogues | HCAR2, AHR, HCAR3 | TRPV1 53/4885KDM4E 2121/4885P4HTM 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.